As we see out September, it’s good to look at what is imminent. During October/November I expect the signing of the US agreement and the FDA approval. Please add to these:
- AZD0466 to commence clinical trials in FY19 (from p.18 SPL annual report). Patent application subsequently published and announced 31 August 2018
- Dep irinotecan to commence clinical trials and final preclinical work underway in preparation (p.15 annual report)
- FDA approval 6-8 months from submission date on 30 April 2018.
- Announcement of US vivagel distributor, described as in “advanced negotiations” on p3 of the annual report.
- further DEP portfolio milestones in the year ahead (again from page 2 of the annual report).
As we see out September, it’s good to look at what is imminent....
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $39.17M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | 9.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.8¢ | 65000 | 1 |
View Market Depth
| Last trade - 16.12pm 25/07/2024 (20 minute delay) ? |
| SPL (ASX) Chart |
Day chart unavailable